Sterling Capital Management’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.92K Buy
2,392
+590
+33% +$690 ﹤0.01% 3069
2026
Q2
$1.93K Buy
1,802
+1,139
+172% +$3.32K ﹤0.01% 2999
2026
Q1
$2.49K Buy
663
+192
+41% +$757 ﹤0.01% 2944
2025
Q4
$1.66K Buy
471
+295
+168% +$1.2K ﹤0.01% 3088
2025
Q3
$704 Buy
176
+1
+0.6% +$3 ﹤0.01% 3128
2025
Q2
$469 Sell
175
-422
-71% -$888 ﹤0.01% 3159
2025
Q1
$842 Sell
597
-535
-47% -$909 ﹤0.01% 2868
2024
Q4
$2.25K Buy
1,132
+1,000
+758% +$2.62K ﹤0.01% 2755
2024
Q3
$416 Buy
+132
New +$416 ﹤0.01% 2943

Other funds holding ADCT

Sterling Capital Management's ADCT Position: Q3 2026 in Review

Sterling Capital Management increased its ADC Therapeutics (ADCT) stake by 33% in Q3 2026, buying an estimated $690 and bringing the position to 2,392 shares worth $2.92K. The position accounts for ﹤0.01% of the portfolio, ranked #3069.

Sterling Capital Management first reported a position in ADCT in Q3 2024 and has held it in 9 quarters since. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Sterling Capital Management held 2,392 shares of ADC Therapeutics worth $2.92K as of Q3 2026.
  • Sterling Capital Management bought 590 ADC Therapeutics shares in Q3 2026, an estimated $690.
  • ADC Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3069 holding.
  • Sterling Capital Management first reported a position in ADC Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.